Investing
Bristol Myers wins dismissal of lawsuit over Celgene drugs
© Reuters. FILE PHOTO: A sign stands outside a Bristol Myers Squibb facility in Cambridge, Massachusetts, U.S., May 20, 2021. REUTERS/Brian Snyder
NEW YORK (Reuters) – A U.S. judge on Wednesday dismissed a lawsuit accusing Bristol Myers (NYSE:) Squibb Co of defrauding investors who stood to receive $6.4 billion had it won federal approval by specified deadlines for drugs developed by the former Celgene Corp (NASDAQ:).
Read the full article here